Compare CMTV & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMTV | TNXP |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.5M | 199.7M |
| IPO Year | 1995 | 2008 |
| Metric | CMTV | TNXP |
|---|---|---|
| Price | $41.05 | $12.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.4K | ★ 457.6K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.02 | ★ 91.75 |
| EPS | ★ 1.62 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $25.05 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $29.53 | $9.40 |
| 52 Week High | $43.76 | $39.45 |
| Indicator | CMTV | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 55.52 |
| Support Level | $38.56 | $11.98 |
| Resistance Level | $41.72 | $13.36 |
| Average True Range (ATR) | 1.85 | 0.84 |
| MACD | 0.07 | 0.16 |
| Stochastic Oscillator | 50.73 | 61.57 |
Community Bancorp Inc is a holding company that provides a complete line of personal and business banking services with personal services and solutions. The company mainly offers Business banking, Commercial real estate lending, residential real estate lending, Retail credit, Municipal and Institutional Banking, and Retail Banking. The company's primary lending products are commercial, real estate, municipal, and consumer loans. The bank offers a complete line of personal and business products and services, along with offerings for non-profit organizations, municipalities, and local governments. The Firm also engages in lending activity outside the area of its branch network, through loan production offices in Burlington, Vermont, and Lebanon, New Hampshire.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.